<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-570
Date of Submission: 2025-06-12

This report was submitted by a Other Healthcare Professional from Sellers PLC Medical Center concerning patient ANON-PX-4615. The subject is a 58-year-old male with a significant medical history including chronic kidney disease, anxiety, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 80mg, initiated on 2025-05-25 for Thromboembolism prevention and discontinued on 2025-06-04.

On approximately 2025-05-26, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Anaphylaxis, Pruritus, Dizziness. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed student and advised former. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-570
report_date: '2025-06-12'
patient_details:
  patient_id: ANON-PX-4615
  gender: Male
  relevant_history:
  - chronic kidney disease
  - anxiety
  - migraines
  age_at_reaction: 58
suspected_drugs:
- drug_name: Warfarin
  dosage: 80mg
  route_of_administration: Intravenous
  start_date: '2025-05-25'
  indication_for_use: Thromboembolism prevention
  drug_class: Anticoagulant
  end_date: '2025-06-04'
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2025-05-26'
  severity: Severe
  outcome: Unknown
  intervention_required: true
  intervention_details: Prescribed student and advised former.
- symptom_name: Anaphylaxis
  onset_date: '2025-05-26'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Pruritus
  onset_date: '2025-05-26'
  severity: Life-threatening
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Dizziness
  onset_date: '2025-05-26'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: true
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Rechallenge not performed
  naranjo_score: 6
reporting_facility: Sellers PLC Medical Center
reporter_type: Other Healthcare Professional
